Page 673 - Williams Hematology ( PDFDrive )

648 Part VI: The Erythrocyte Chapter 43: Iron Deficiency and Overload 649

Agency for Healthcare Research and Quality, Rockville, MD, 2013. Available at: http:// 228. Ramos E, Kautz L, Rodriguez R, et al: Evidence for distinct pathways of hepcidin regu-
www.ncbi.nlm.nih.gov/books/NBK242350/ (last accessed 14 January 2015). lation by acute and chronic iron loading in mice. Hepatology 53(4):1333–1341, 2011.
192. Hilal H, McCurdy PR: A pitfall in the interpretation of serum iron values. Ann Intern 229. Bridle KR, Frazer DM, Wilkins SJ, et al: Disrupted hepcidin regulation in HFE-associ-
MedIntern Med 66(5):983–988, 1967. ated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet
193. Rockey DC: Occult gastrointestinal bleeding. Gastroenterol Clin North Am 34(4):699– 361:669–673, 2003.
718, 2005. 230. Nemeth E, Roetto A, Garozzo G, et al: Hepcidin is decreased in TFR2 hemochromato-
194. Hallberg L, Ryttinger L, Solvell L: Side-effects of oral iron therapy. A double-blind study sis. Blood 105(4):1803–1806, 2005.
of different iron compounds in tablet form. Acta Med Scand Suppl 459:3–10, 1966. 231. Papanikolaou G, Samuels ME, Ludwig EH, et al: Mutations in HFE2 cause iron over-
195. Leung AK, Chan KW: Iron deficiency anemia. Adv Pediatr 48:385–408, 2001. load in chromosome 1q-linked juvenile hemochromatosis. Nat Genet 36(1):77–82,
196. Gordeuk VR, Brittenham GM, Hughes M, et al: High-dose carbonyl iron for iron defi- 2004.
ciency anemia: A randomized double-blind trial. Am J Clin Nutr 46(6):1029–1034, 232. Sham RL, Phatak PD, Nemeth E, et al: Hereditary hemochromatosis due to resistance to
1987. hepcidin: High hepcidin concentrations in a family with C326S ferroportin mutation.
197. Harding KB, Neufeld LM: Iron deficiency and anemia control for infants and young Blood 114(2):493–494, 2009.
children in malaria-endemic areas: A call to action and consensus among the research 233. Fernandes A, Preza GC, Phung Y, et al: The molecular basis of hepcidin-resistant hered-
community. Adv Nutr 3(4):551–554, 2012. itary hemochromatosis. Blood 114(2):437–443, 2009.
198. Chang TP, Rangan C: Iron poisoning: A literature-based review of epidemiology, diag- 234. Tanno T, Bhanu NV, Oneal PA, et al: High levels of GDF15 in thalassemia suppress
nosis, and management. Pediatr Emerg Care 27(10):978–985, 2011. expression of the iron regulatory protein hepcidin. Nat Med 13(9):1096–1101, 2007.
199. Susantitaphong P, Alqahtani F, Jaber BL: Efficacy and safety of intravenous iron therapy 235. Kautz L, Jung G, Valore EV, et al: Identification of erythroferrone as an erythroid regu-
for functional iron deficiency anemia in hemodialysis patients: A meta-analysis. Am J lator of iron metabolism. Nat Genet 46(7):678–684, 2014.
Nephrol 39(2):130–141, 2014. 236. Tamary H, Shalev H, Perez-Avraham G, et al: Elevated growth differentiation fac-
200. Taylor JE, Peat N, Porter C, et al: Regular low-dose intravenous iron therapy improves tor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood
response to erythropoietin in haemodialysis patients. Nephrol Dial Transplant 112(13):5241–5244, 2008.
11(6):1079–1083, 1996. 237. Casanovas G, Swinkels DW, Altamura S, et al: Growth differentiation factor 15 in
201. Rodgers GM, Auerbach M, Cella D, et al: High-molecular weight iron dextran: A wolf patients with congenital dyserythropoietic anaemia (CDA) type II. J Mol Med (Berl)
in sheep’s clothing? J Am Soc Nephrol 19(5):833–834, 2008. 89(8):811–816, 2011.
202. Bircher AJ, Auerbach M: Hypersensitivity from intravenous iron products. Immunol 238. Barton JC, Acton RT, Rivers CA, et al: Genotypic and phenotypic heterogeneity of African
Allergy Clin North Am 34(3):707–723, 2014. Americans with primary iron overload. Blood Cells Mol Dis 31(3):310–319, 2003.
203. Aslan D, Crain K, Beutler E: A new case of human atransferrinemia with a previously 239. Sham RL, Phatak PD, West C, et al: Autosomal dominant hereditary hemochromatosis
undescribed mutation in the transferrin gene. Acta Haematol 118(4):244–247, 2007. associated with a novel ferroportin mutation and unique clinical features. Blood Cells
204. Chen C, Wen S, Tan X: Molecular analysis of a novel case of congenital atransferrine- Mol Dis 34(2):157–161, 2005.
mia. Acta Haematol 122(1):27–28, 2009. 240. Porter JB, Garbowski M: The pathophysiology of transfusional iron overload. Hematol
205. Knisely AS, Gelbart T, Beutler E: Molecular characterization of a third case of human Oncol Clin North Am 28(4):683–701, vi, 2014.
atransferrinemia. Blood 104(8):2607, 2004. 241. Pietrangelo A: Juvenile hemochromatosis. J Hepatol 45(6):892–894, 2006.
206. Shamsian BS, Rezaei N, Arzanian MT, et al: Severe hypochromic microcytic anemia in 242. Anderson LJ: Assessment of iron overload with T2* magnetic resonance imaging. Prog
a patient with congenital atransferrinemia. Pediatr Hematol Oncol 26(5):356–362, 2009. Cardiovasc Dis 54(3):287–294, 2011.
207. Iolascon A, De Falco L: Mutations in the gene encoding DMT1: Clinical presentation 243. Herring WB, Gay RM: Absence of stainable bone marrow iron in hemochromatosis.
and treatment. Semin Hematol 46(4):358–370, 2009. South Med J 74(9):1088–1089, 1094, 1981.
208. Mims MP, Guan Y, Pospisilova D, et al: Identification of a human mutation of DMT1 in 244. Camaschella C, Poggiali E: Inherited disorders of iron metabolism. Curr Opin Pediatr-
a patient with microcytic anemia and iron overload. Blood 105(3):1337–1342, 2005. Pediatrics 23(1):14–20, 2011.
209. Whitington PF: Gestational alloimmune liver disease and neonatal hemochromatosis. 245. Beutler E, Felitti VJ, Ho NJ, et al: Commentary on HFE S65C variant is not associated
Semin Liver Dis 32(4):325–332, 2012. with increased transferrin saturation in voluntary blood donors by Naveen Arya, Sub-
210. Davis WD Jr, Arrowsmith WR: The treatment of hemochromatosis by massive venesec- rata Chakrabrati, Robert A. Hegele, Paul C. Adams. Blood Cells Mol Dis 25(6):358–360,
tion. Ann Intern Med 39(4):723–734, 1953. 1999.
211. MacDonald RA: Hemochromatosis: A perlustration. Am J Clin Nutr 23(5):592–603, 246. Roetto A, Papanikolaou G, Politou M, et al: Mutant antimicrobial peptide hepcidin is
1970. associated with severe juvenile hemochromatosis. Nat Genet 33(1):21–22, 2003.
212. Feder JN, Gnirke A, Thomas W, et al: A novel MHC class I-like gene is mutated in 247. Altamura S, Kessler R, Gr+¦ne HJ, et al: Resistance of ferroportin to hepcidin binding
patients with hereditary haemochromatosis. Nat Genet 13(4):399–408, 1996. causes exocrine pancreatic failure and fatal iron overload. Cell Metab 20(2):359–367,
213. Beutler E: Iron storage disease: Facts, fiction and progress. Blood Cells Mol Dis 2014.
39(2):140–147, 2007. 248. Wallace DF, Harris JM, Subramaniam VN: Functional analysis and theoretical model-
214. Lucotte G, Dieterlen F: A European allele map of the C282Y mutation of hemochroma- ing of ferroportin reveals clustering of mutations according to phenotype. Am J Physiol
tosis: Celtic versus Viking origin of the mutation? Blood Cells Mol Dis 31(2):262–267, Cell Physiol 298(1):C75–C84, 2010.
2003. 249. Barton JC, Acton RT, Lee PL, et al: SLC40A1 Q248H allele frequencies and Q248H-as-
215. Adams PC, Deugnier Y, Moirand R, et al: The relationship between iron overload, sociated risk of non-HFE iron overload in persons of sub-Saharan African descent.
clinical symptoms, and age in 410 patients with genetic hemochromatosis. Hepatology Blood Cells Mol Dis 39(2):206–211, 2007.
25(1):162–166, 1997. 250. Rivers CA, Barton JC, Gordeuk VR, et al: Association of ferroportin Q248H polymor-
216. McDonnell SM, Preston BL, Jewell SA, et al: A survey of 2,851 patients with hemochro- phism with elevated levels of serum ferritin in African Americans in the Hemochroma-
matosis: Symptoms and response to treatment. Am J Med 106(6):619–624, 1999. tosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol Dis 38(3):247–252,
217. Waalen J, Felitti V, Gelbart T, et al: Prevalence of hemochromatosis-related symptoms 2007.
among individuals with mutations in the HFE gene. Mayo Clin Proc 77(6):522–530, 251. Girelli D, Trombini P, Busti F, et al: A time course of hepcidin response to iron challenge
2002. in patients with HFE and TFR2 hemochromatosis. Haematologica 96(4):500–506, 2011.
218. Allen KJ, Gurrin LC, Constantine CC, et al: Iron-overload-related disease in HFE 252. Kawabata H, Fleming RE, Gui D, et al: Expression of hepcidin is down-regulated in
hereditary hemochromatosis. N Engl J Med 358(3):221–230, 2008. TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis. Blood
219. Beutler E: The HFE Cys282Tyr mutation as a necessary but not sufficient cause of clin- 105(1):376–381, 2005.
ical hereditary hemochromatosis. Blood 101(9):3347–3350, 2003. 253. Camaschella C, Roetto A, Cali A, et al: The gene TFR2 is mutated in a new type of
220. Rossi E, Olynyk JK, Jeffrey GP: Clinical penetrance of C282Y homozygous HFE hemo- haemochromatosis mapping to 7q22. Nat Genet 25(1):14–15, 2000.
chromatosis. Expert Rev Hematol 1(2):205–216, 2008. 254. Huang FW, Babitt JL, Wrighting DM, et al: Hemojuvelin acts as a bone morphoge-
221. Bacon BR, Britton RS: Clinical penetrance of hereditary hemochromatosis. N Engl J netic protein co-receptor to regulate hepcidin expression. ASH Annu Meet Abstr.
Med 358(3):291–292, 2008. 106(11):511, 2005.
222. Fletcher LM, Powell LW: Hemochromatosis and alcoholic liver disease. Alcohol 255. Niederkofler V, Salie R, Arber S: Hemojuvelin is essential for dietary iron sensing, and
30(2):131–136, 2003. its mutation leads to severe iron overload. J Clin Invest 115(8):2180–2186, 2005.
223. Fletcher LM, Dixon JL, Purdie DM, et al: Excess alcohol greatly increases the prev- 256. Huang FW, Pinkus JL, Pinkus GS, et al: A mouse model of juvenile hemochromatosis.
alence of cirrhosis in hereditary hemochromatosis. Gastroenterology 122(2):281–289, J Clin Invest 115(8):2187–2191, 2005.
2002. 257. Lee PL, Beutler E, Rao SV, et al: Genetic abnormalities and juvenile hemochromatosis:
224. McCord JM: Iron, free radicals, and oxidative injury. Semin Hematol 35(1):5–12, 1998. Mutations of the HJV gene encoding hemojuvelin. Blood 103(12):4669–4671, 2004.
225. Carthew P, Dorman BM, Edwards RE, et al: A unique rodent model for both the car- 258. Lanzara C, Roetto A, Daraio F, et al: Spectrum of hemojuvelin gene mutations in
diotoxic and hepatotoxic effects of prolonged iron overload. Lab Invest 69(2):217–222, 1q-linked juvenile hemochromatosis. Blood 103(11):4317–4321, 2004.
1993. 259. Steinbicker AU, Bartnikas TB, Lohmeyer LK, et al: Perturbation of hepcidin expres-
226. Tsukamoto H, Horne W, Kamimura S, et al: Experimental liver cirrhosis induced by sion by BMP type I receptor deletion induces iron overload in mice. Blood 118(15):
alcohol and iron. J Clin Invest 96(1):620–630, 1995. 4224–4230, 2011.
227. Arosio P, Ingrassia R, Cavadini P: Ferritins: A family of molecules for iron storage, 260. Blanco E, Kannengiesser C, Grandchamp B, et al: Not all DMT1 mutations lead to iron
antioxidation and more. Biochim Biophys Acta 1790(7):589–599, 2009. overload. Blood Cells Mol Dis 43(2):199–201, 2009.

Kaushansky_chapter 43_p0627-0650.indd 648 9/17/15 6:27 PM